Last reviewed · How we verify

PrabotulinumtoxinA-Xvfs — Competitive Intelligence Brief

PrabotulinumtoxinA-Xvfs (PrabotulinumtoxinA-Xvfs) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum toxin type A. Area: Dermatology / Aesthetics.

marketed Botulinum toxin type A SNARE complex (acetylcholine release machinery) Dermatology / Aesthetics Small molecule Live · refreshed every 30 min

Target snapshot

PrabotulinumtoxinA-Xvfs (PrabotulinumtoxinA-Xvfs) — Lupo Center for Aesthetic and General Dermatology. PrabotulinumtoxinA-Xvfs is a botulinum toxin type A that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PrabotulinumtoxinA-Xvfs TARGET PrabotulinumtoxinA-Xvfs Lupo Center for Aesthetic and General Dermatology marketed Botulinum toxin type A SNARE complex (acetylcholine release machinery)
powder BoNT-A (BOTOX/Vistabel) powder BoNT-A (BOTOX/Vistabel) Galderma R&D marketed Neurotoxin; botulinum toxin type A SNAP-25 (synaptosome-associated protein of 25 kDa)
Botox 100 UNT Injection Botox 100 UNT Injection Brigitte Schürch marketed Botulinum toxin type A SNAP-25 (synaptosome-associated protein of 25 kDa)
incabotulinumtoxinA incabotulinumtoxinA Multiple Sclerosis Center of Northeastern New York marketed Botulinum toxin type A SNARE complex (synaptobrevin/VAMP)
Botox Cosmetic™ Botox Cosmetic™ Carruthers Dermatology Centre marketed Botulinum toxin type A SNAP-25 (synaptosome-associated protein of 25 kDa)
Xeomin® Xeomin® ATGC Co., Ltd. marketed Botulinum toxin type A SNARE complex (acetylcholine release machinery at neuromuscular junction)
NT 201 NT 201 Merz Aesthetics GmbH marketed Botulinum toxin type A SNARE complex (acetylcholine release machinery)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum toxin type A class)

  1. Merz North America, Inc. · 2 drugs in this class
  2. Department of Medical Services Ministry of Public Health of Thailand · 2 drugs in this class
  3. Brigitte Schürch · 1 drug in this class
  4. Carruthers Dermatology Centre · 1 drug in this class
  5. Galderma R&D · 1 drug in this class
  6. Huons Co., Ltd. · 1 drug in this class
  7. Innovaderm Research Inc. · 1 drug in this class
  8. Lupo Center for Aesthetic and General Dermatology · 1 drug in this class
  9. Merz Aesthetics GmbH · 1 drug in this class
  10. Multiple Sclerosis Center of Northeastern New York · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PrabotulinumtoxinA-Xvfs — Competitive Intelligence Brief. https://druglandscape.com/ci/prabotulinumtoxina-xvfs. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: